BMS Does Not Think Pricing Or Monitoring Will Limit Camzyos Use
First-In-Class Drug’s List Price Is $89,500 Per Year
Executive Summary
Bristol already is training cardiologists at major treatment centers in how to treat obstructive hypertrophic cardiomyopathy with Camzyos (mavacamten) based on the REMS in the US label.